BNP Paribas Financial Markets Invests $532,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

BNP Paribas Financial Markets bought a new stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 95,424 shares of the company's stock, valued at approximately $532,000. BNP Paribas Financial Markets owned approximately 0.21% of 4D Molecular Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently bought and sold shares of FDMT. Vanguard Group Inc. boosted its stake in shares of 4D Molecular Therapeutics by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock worth $15,933,000 after acquiring an additional 92,791 shares during the period. JPMorgan Chase & Co. raised its position in shares of 4D Molecular Therapeutics by 159.5% during the fourth quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock valued at $4,568,000 after buying an additional 504,086 shares during the last quarter. Norges Bank purchased a new position in shares of 4D Molecular Therapeutics in the fourth quarter worth $2,790,000. Northern Trust Corp lifted its holdings in shares of 4D Molecular Therapeutics by 2.3% in the fourth quarter. Northern Trust Corp now owns 440,665 shares of the company's stock worth $2,455,000 after buying an additional 9,982 shares in the last quarter. Finally, Decheng Capital LLC boosted its position in shares of 4D Molecular Therapeutics by 0.5% during the fourth quarter. Decheng Capital LLC now owns 400,000 shares of the company's stock worth $2,228,000 after acquiring an additional 2,165 shares during the last quarter. Institutional investors own 99.27% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on FDMT. Royal Bank of Canada cut their price objective on 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. The Goldman Sachs Group lowered their target price on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a research report on Friday, May 9th. HC Wainwright restated a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Barclays lowered their price objective on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. Finally, Chardan Capital reduced their target price on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating on the stock in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $29.56.

4D Molecular Therapeutics Trading Down 2.0%

Shares of FDMT stock traded down $0.07 during trading hours on Tuesday, reaching $3.42. 293,635 shares of the stock were exchanged, compared to its average volume of 833,970. The firm has a market capitalization of $158.43 million, a price-to-earnings ratio of -1.20 and a beta of 2.87. 4D Molecular Therapeutics, Inc. has a 12-month low of $2.24 and a 12-month high of $28.93. The company's 50-day moving average price is $3.25 and its 200-day moving average price is $4.88.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.02). On average, sell-side analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.